Skip to main content

Healthy Participants

194
Pipeline Programs
30
Companies
50
Clinical Trials
6 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
191
1
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2659%
Monoclonal Antibody
920%
RNA Therapeutic
49%
Peptide
37%
Vaccine
25%
+ 284 programs with unclassified modality

Competitive Landscape

88 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
40 programs
39
1
mPnC candidatePhase 21 trial
Bosutinib capsulePhase 11 trial
Bosutinib capsulePhase 11 trial
Bosutinib capsulePhase 11 trial
DabigatranPhase 11 trial
+35 more programs
Active Trials
NCT04549480Completed66Est. Jan 2021
NCT05032690Completed32Est. Jun 2022
NCT04916769Completed18Est. Jan 2022
+35 more trials
Cidara Therapeutics
1
1
CD388 InjectionPhase 2
Fluzone HD influenza vaccinePhase 1Vaccine
Tangram Therapeutics
1
TGM-312-SC01Phase 1/21 trial
Active Trials
NCT07427680Recruiting99Est. Jun 2028
AstraZeneca
36 programs
36
ALXN1920Phase 11 trial
ALXN2050 MR Prototype TabletPhase 11 trial
AZD0292Phase 11 trial
AZD0780Phase 11 trial
AZD0780Phase 11 trial
+31 more programs
Active Trials
NCT05751642Completed48Est. Dec 2023
NCT05780645Completed80Est. Feb 2024
NCT07222254Active Not Recruiting18Est. Jul 2026
+35 more trials
Bristol Myers Squibb
20 programs
1
NavlimetostatPhase 1Small Molecule1 trial
AdmilparantPHASE_12 trials
BMS-986036PHASE_13 trials
BMS-986165PHASE_11 trial
BMS-986165PHASE_11 trial
+15 more programs
Active Trials
NCT07441408Not Yet Recruiting2,277Est. Mar 2030
NCT07225647Completed56Est. Jan 2026
NCT04634149Completed16Est. Jun 2022
+46 more trials
Incyte
17 programs
17
AxatilimabPhase 1Monoclonal Antibody1 trial
DigoxinPhase 11 trial
INCA033989Phase 11 trial
INCB000631Phase 11 trial
INCB000631Phase 11 trial
+12 more programs
Active Trials
NCT06713590Completed72Est. Jun 2025
NCT06416800Completed71Est. Jan 2025
NCT07448155Active Not Recruiting72Est. May 2026
+16 more trials
Prevail Therapeutics
15
BaricitinibPhase 1Small Molecule
DC-806Phase 1
Insulin LisproPhase 1
LY2409021Phase 1
LY2484595Phase 1
+10 more programs
Lundbeck
9 programs
9
Eptinezumab Mammalian Cell LinePhase 11 trial
Lu AF28996Phase 11 trial
Lu AF28996Phase 11 trial
Lu AF82422Phase 11 trial
Lu AG06466Phase 11 trial
+4 more programs
Active Trials
NCT05074459Completed84Est. Jul 2022
NCT06277609Completed22Est. May 2024
NCT06337110Completed8Est. May 2024
+6 more trials
Genentech
8 programs
5
FenebrutinibPhase 1Small Molecule1 trial
GantenerumabPhase 1Monoclonal Antibody1 trial
Immunoglobulin GPhase 11 trial
RO7795081Phase 11 trial
ZN-A-1041Phase 11 trial
+3 more programs
Active Trials
NCT01929876Completed16Est. Oct 2013
NCT06835465Completed18Est. May 2025
NCT03174041Completed63Est. Jun 2017
+5 more trials
Amgen
AmgenTHOUSAND OAKS, CA
8 programs
8
AMG 133Phase 15 trials
AMG 510Phase 15 trials
AMG 510Phase 11 trial
AMG 510Phase 11 trial
AMG 510Phase 11 trial
+3 more programs
Active Trials
NCT07313761Active Not Recruiting349Est. Jun 2026
NCT07226778Active Not Recruiting348Est. May 2026
NCT07429032Completed57Est. Nov 2025
+13 more trials
BioTherapeutics Inc
4
BBT-877Phase 1
BBT-877 single dosePhase 1
LTG-321Phase 1
PlixorafenibPhase 1Small Molecule
Biocorp
3 programs
1
JMT206Phase 11 trial
Alpha-Glycerophosphocholine(α-GPC)N/A1 trial
Bacillus subtilis MB40N/A1 trial
Active Trials
NCT07267845Recruiting80Est. Jul 2026
NCT04655352Completed30Est. Dec 2015
NCT07419698Recruiting44Est. Nov 2026
Quotient Therapeutics
3
AZD5004 film-coated tabletPhase 1
AZD6234 Formulation 1Phase 1
[14C]AZD4144 Solution for InfusionPhase 1
Xentria
3 programs
3
MAB-22Phase 11 trial
NKF-INSPhase 11 trial
NKF-INSPhase 11 trial
Active Trials
NCT06310824Completed225Est. Jul 2025
NCT06627478Completed114Est. Jul 2025
NCT06492226Completed54Est. Oct 2024
Shionogi
3 programs
3
RosuvastatinPhase 1Small Molecule1 trial
S-740792 SuspensionPhase 11 trial
S-892216-LAIPhase 11 trial
Active Trials
NCT07011992Completed12Est. Aug 2025
NCT06724978Completed99Est. Sep 2025
NCT07093580Recruiting98Est. May 2027
Deciphera Pharmaceuticals
3
VimseltinibPhase 1Small Molecule1 trial
VimseltinibPhase 1Small Molecule1 trial
VimseltinibPhase 1Small Molecule1 trial
Active Trials
NCT07158411Completed22Est. Jan 2026
NCT07158398Completed20Est. Dec 2025
NCT07539090Not Yet Recruiting24Est. Jun 2026
Innovation Pharmaceuticals
1
Debio 1453PPhase 1
Commercially available high-protein yoghurt drinkN/A1 trial
Active Trials
NCT07497113Completed62Est. Feb 2026
UNION therapeutics
1
HZBio1 0.96mg / kgPhase 1
Transformative Virtual Reality Experience and ACT for General PractitionersN/A1 trial
Active Trials
NCT07140705Completed21Est. Nov 2025
Acerta Pharma
2 programs
2
ACP-196Phase 11 trial
ACP-196Phase 11 trial
Active Trials
NCT04914936Completed72Est. Oct 2014
NCT04901923Completed59Est. May 2014
EA Pharma
2 programs
2
AJM347Phase 11 trial
E6130Phase 11 trial
Active Trials
NCT03133468Completed200Est. Jul 2018
NCT03390647Withdrawn0Est. Mar 2019
Bridge Biotherapeutics
2
BBT-877Phase 11 trial
BBT-877 single dosePhase 11 trial
Active Trials
NCT04138836Completed48Est. Nov 2019
NCT04138849Completed24Est. Oct 2019
Kite Pharma
2 programs
2
EtrumadenantPhase 1
[14C]-etrumadenantPhase 1
Kexing Biopharm
2 programs
2
Human interferon alfa 1b inhalation solutionPhase 11 trial
SHEN26 capsulePhase 11 trial
Active Trials
NCT06277167Completed35Est. Apr 2023
NCT05504746Completed86Est. Dec 2022
Innovent Biologics
2
IBI3002Phase 11 trial
IBI356 for MADPhase 11 trial
Active Trials
NCT06213844Completed52Est. Sep 2025
NCT06193434Completed99Est. Aug 2025
AC Immune
AC Immune1015 LAUSANNE, Switzerland
1 program
1
ACI-19764Phase 11 trial
Active Trials
NCT07463196Recruiting78Est. Aug 2026
Agios Pharmaceuticals
1
AG-881Phase 11 trial
Active Trials
NCT04015687Completed22Est. Oct 2019
Ark Biosciences
1
AK0406Phase 11 trial
Active Trials
NCT07432698Not Yet Recruiting32Est. Apr 2027
Astellas
AstellasChina - Shenyang
1 program
1
ASP8731Phase 11 trial
Active Trials
NCT05167526Terminated36Est. Nov 2022
Aeovian Pharmaceuticals
1
AV078Phase 11 trial
Active Trials
NCT06205381Completed89Est. Feb 2025
BeiGene
1 program
1
BGB-45035Phase 1

+58 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Bristol Myers SquibbMethotrexate
Bristol Myers SquibbAdmilparant
Qilu PharmaceuticalQL2106
IncyteINCB161734
Bristol Myers SquibbMethotrexate
RegeneronREGN10933 + REGN10987
AmgenAMG 510
Bristol Myers SquibbBMS-986205
TevaTbo-filgrastim
Bristol Myers SquibbMethotrexate
Bristol Myers SquibbMethotrexate
Bristol Myers SquibbMethotrexate
Bristol Myers SquibbMethotrexate
Bristol Myers SquibbMethotrexate
Bristol Myers SquibbMethotrexate

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 17,385 patients across 50 trials

Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis

Start: Nov 2015Est. completion: Mar 201980 patients
Phase 4Completed

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

Start: Dec 2026Est. completion: Mar 20302,277 patients
Phase 3Not Yet Recruiting

A Phase 3 Clinical Study of QL2106 Injection

Start: Jun 2026Est. completion: Feb 2028318 patients
Phase 3Not Yet Recruiting

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Start: Apr 2026Est. completion: Mar 2029588 patients
Phase 3Recruiting

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Start: Sep 2021Est. completion: Sep 2027338 patients
Phase 3Active Not Recruiting
NCT04452318RegeneronREGN10933 + REGN10987

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

Start: Jul 2020Est. completion: Oct 20213,303 patients
Phase 3Completed

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

Start: Jun 2020Est. completion: Jun 2026345 patients
Phase 3Active Not Recruiting

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Start: May 2018Est. completion: Aug 20250
Phase 3Withdrawn
NCT03029000TevaTbo-filgrastim

Study of the Effect of a 5-Day Regimen of Study Drug on Peripheral Stem Cell Mobilization in Healthy Participants

Start: Aug 2017Est. completion: Oct 20171 patients
Phase 3Terminated

Effects of Abatacept in Patients With Early Rheumatoid Arthritis

Start: Sep 2015Est. completion: Mar 2020994 patients
Phase 3Completed

Methotrexate-Inadequate Response Autoinjector Device Sub Study

Start: Apr 2013Est. completion: Jul 2014120 patients
Phase 3Completed

Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis

Start: Dec 2010Est. completion: Oct 2014511 patients
Phase 3Completed

Methotrexate - Inadequate Response Device Sub-Study

Start: Nov 2009Est. completion: Jul 201062 patients
Phase 3Completed

A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Start: Apr 2007Est. completion: Dec 2011113 patients
Phase 3Completed

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

Start: Jul 2005Est. completion: Feb 20091,052 patients
Phase 3Completed

Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis

Start: Feb 2005Est. completion: Jul 2009431 patients
Phase 3Completed

A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

Start: Dec 2002Est. completion: Oct 20091,250 patients
Phase 3Completed

Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)

Start: Aug 2002Est. completion: Sep 2006720 patients
Phase 3Completed

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Start: Nov 2025Est. completion: Dec 202865 patients
Phase 2Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

Start: Jun 2025Est. completion: Jan 2028120 patients
Phase 2Recruiting

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

Start: Jun 2025Est. completion: Jun 2027200 patients
Phase 2Recruiting
NCT06116591PfizermPnC candidate

A Phase 2 Study to Learn About a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers

Start: Nov 2023Est. completion: May 2024105 patients
Phase 2Completed

A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

Start: Apr 2023Est. completion: Aug 2024109 patients
Phase 2Completed

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

Start: Jan 2023Est. completion: Dec 2025592 patients
Phase 2Completed

A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

Start: Mar 2022Est. completion: Oct 202727 patients
Phase 2Recruiting

A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

Start: Jan 2022Est. completion: May 202542 patients
Phase 2Completed

A Study of TAK-994 in Adults With Narcolepsy

Start: Apr 2021Est. completion: Nov 202126 patients
Phase 2Terminated

A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy

Start: May 2020Est. completion: Nov 202197 patients
Phase 2Terminated

Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation

Start: Nov 2019Est. completion: Jun 202343 patients
Phase 2Completed

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Start: Sep 2019Est. completion: Dec 20190
Phase 2Withdrawn

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Start: Aug 2018Est. completion: Aug 2022142 patients
Phase 2Terminated

Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis

Start: Feb 2016Est. completion: May 2018508 patients
Phase 2Completed

Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis

Start: Oct 2013Est. completion: Feb 201647 patients
Phase 2Completed

PoC in Rheumatoid Arthritis With Methotrexate

Start: Mar 2008Est. completion: Sep 2009121 patients
Phase 2Completed

A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate

Start: Jun 2006Est. completion: Nov 2007194 patients
Phase 2Completed

Abatacept With Methotrexate- Phase IIB

Start: Oct 2000Est. completion: Sep 2009524 patients
Phase 2Completed

Study of TGM-312-SC01 in Healthy Participants and Adults With MASH

Start: Feb 2026Est. completion: Jun 202899 patients
Phase 1/2Recruiting

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Start: Nov 2023Est. completion: Oct 203085 patients
Phase 1/2Active Not Recruiting

A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors

Start: Dec 2018Est. completion: Dec 202012 patients
Phase 1/2Completed

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Start: Oct 2018Est. completion: Mar 20218 patients
Phase 1/2Terminated

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Start: Aug 2018Est. completion: May 2026713 patients
Phase 1/2Active Not Recruiting

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Start: Apr 2016Est. completion: Oct 2021627 patients
Phase 1/2Completed

Study of STLX-2012 in Healthy Volunteers

Start: Oct 2026Est. completion: Feb 202732 patients
Phase 1Not Yet Recruiting

A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment

Start: May 2026Est. completion: Apr 202716 patients
Phase 1Not Yet Recruiting

A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease

Start: May 2026Est. completion: Jan 202716 patients
Phase 1Not Yet Recruiting

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

Start: May 2026Est. completion: Jun 202624 patients
Phase 1Not Yet Recruiting

A Phase 1 Study of Navlimetostat Tablet Formulations

Start: Apr 2026Est. completion: Oct 202664 patients
Phase 1Not Yet Recruiting

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

Start: Mar 2026Est. completion: Jul 2030120 patients
Phase 1Not Yet Recruiting

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants

Start: Mar 2026Est. completion: May 202672 patients
Phase 1Active Not Recruiting

A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants

Start: Mar 2026Est. completion: Jul 202632 patients
Phase 1Active Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

6 actively recruiting trials targeting 17,385 patients
30 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.